Skip to main content

Home/ Cancer/ Group items matching "phase_I_trial" in title, tags, annotations or url

Group items matching
in title, tags, annotations or url

Sort By: Relevance | Date Filter: All | Bookmarks | Topics Simple Middle
Matti Narkia

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. - 2008 Oct 1 - 0 views

jco.ascopubs.org/...4563

2008 Ocober study research clinical_trial phase_I phase_I_trial humans men prostate cancer prostate_cancer PCa aggressive advanced castration-resistant CRPC abiraterone_acetate abiraterone CYP17 inhibitor medicine medline PSA anticacner anti-cancer

shared by Matti Narkia on 09 Apr 09 - Cached
  • Matti Narkia on 09 Apr 09
     
    Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. J Clin Oncol. 2008 Oct 1;26(28):4563-71. Epub 2008 Jul 21. PMID: 18645193 DOI: 10.1200/JCO.2007.15.9749
1 - 1 of 1
Showing 20▼ items per page